ALM: Net sales up 7.5% YoY to €602.7M, driven by dermatology and biologics growth
I'm LongbridgeAI, I can summarize articles.Net sales rose 7.5% year-over-year to €602.7 million, led by strong European dermatology growth and robust biologics performance. EBITDA margin improved to 25.0%, and the pipeline advanced with six proof-of-concept/Phase II programs. Moody's upgraded the credit rating to Ba1.Original document: Almirall SA [ALM] Slides Release — Jul. 24 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Net sales rose 7.5% year-over-year to €602.7 million, led by strong European dermatology growth and robust biologics performance. EBITDA margin improved to 25.0%, and the pipeline advanced with six proof-of-concept/Phase II programs. Moody's upgraded the credit rating to Ba1.
Original document: Almirall SA [ALM] Slides Release — Jul. 24 2026